Breaking News Instant updates and real-time market news.

LEN

Lennar

$54.89

2.15 (4.08%)

, REGN

Regeneron

$471.67

11.76 (2.56%)

09:55
06/20/17
06/20
09:55
06/20/17
09:55

Early notable gainers among liquid option names on June 20th

Notable gainers among liquid option names this morning include Lennar (LEN) $55.48 +2.83, Regeneron (REGN) $484.23 +12.73, NVIDIA (NVDA) $161.46 +4.19, LabCorp (LH) $145.30 +3.48, and D R Horton (DHI) $34.66 +0.82.

LEN

Lennar

$54.89

2.15 (4.08%)

REGN

Regeneron

$471.67

11.76 (2.56%)

NVDA

Nvidia

$157.32

5.7 (3.76%)

LH

LabCorp

$144.36

2.465 (1.74%)

DHI

D.R. Horton

$34.75

0.9 (2.66%)

  • 20

    Jun

  • 22

    Jun

  • 26

    Jun

  • 15

    Aug

  • 29

    Aug

LEN Lennar
$54.89

2.15 (4.08%)

03/22/17
RBCM
03/22/17
NO CHANGE
RBCM
Lennar shares should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that Lennar reported "solid" Q1 results. He blames the stock's weakness on "reduced profitability due to higher costs for land and construction coupled with one-time expenses associated with the acquisition of WCI Communities (WCIC)." However, since Lennar reiterated its fiscal 2017 margin guidance and made upbeat comments about its outlook, the weakness was "unwarranted," according to Wetenhall. He raised his price target on the shares to $60 from $53 and keeps an Outperform rating on the stock.
05/16/17
MZHO
05/16/17
INITIATION
Target $59
MZHO
Buy
Lennar initiated with a Buy at Mizuho
Mizuho analyst Haendel St. Juste initiated Lennar with a Buy and a $59 price target.
04/13/17
RAJA
04/13/17
NO CHANGE
Target $60
RAJA
Strong Buy
Lennar added to 'Analyst Current Favorites' at Raymond James
Raymond James analyst Buck Horne added Lennar to the '"Analyst Current Favorites" list and raised its price target to $60, based on last week's S-11 filing from from Five Point Holdings which increases his sum-of-the-parts valuation for the company. Horne now seesnew evidence to suggest that his prior estimates regarding the value of Lennar's equity stake in Five Point was likely too conservative, at $5-6/share previously, versus $9+/share now, due to a larger than expected 45% equity interest in FPH and greater clarity around total entitlements and transaction activity. The analyst rates Lennar a Strong Buy.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
Barclays sees additiona near-term upside for builders
Barclays analyst Michael Dahl says his firm's February survey indicates "strong" early spring demand for U.S. homebuilders. Upcoming catalysts for the group will likely be positive, Dahl tells investors in a research note. The analyst sees "modest" further near-term upside for builder stocks despite the recent rallies. His Overweight rated names are PulteGroup (PHM), Lennar (LEN) and TRI Pointe (TPH). Dahl also believes D.R. Horton (DHI) is well positioned to capture incremental demand. He raised his price target for the shares to $34 from $30 but keeps an Equal Weight rating due to valuation.
REGN Regeneron
$471.67

11.76 (2.56%)

06/20/17
PIPR
06/20/17
NO CHANGE
Target $557
PIPR
Overweight
Piper says buy Regeneron on today's selloff, ups target to $557
Piper Jaffray analyst Edward Tenthoff recommends using today's weakness in shares of Regeneron Pharmaceuticals (REGN) after Novartis (NVS) reported positive Phase III data on brolucizumab as a buying opportunity. While brolucizumab is a competitive threat to Regeneron's Eylea, Novartis will not file until 2018 due to manufacturing issues, Tenthoff tells investors in a research note. He continues to expect Eylea sales growth of 6.1% to $3.52B this year and 5% to $3.7B in 2018 before brolucizumab hits the market in 2019. Tenthoff raised his price target for Regeneron Pharmaceuticals to $557 from $446 to reflect a higher price-to-earnings multiple and reiterates an Overweight rating on the shares. Positive Dupixent Phase III asthma data this fall would dramatically expand the company's market opportunity, he contends.
06/12/17
LEER
06/12/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron's Dupixent tracking well above consensus, says Leerink
Leerink analyst Geoffrey Porges says prescription trends suggest Regeneron (REGN) and Sanofi's (SNY) Dupixent will "comfortably exceed" current sell-side consensus expectations for this quarter and year. After 10 weeks, the prescription launch trajectory "remains very robust," Porges tells investors in a research note. The analyst views his Q2 sales estimate of $31M, versus the $16M consensus, as "reasonable," and feels full year sales of $200M-300M, versus the consensus of $135-$140M, is likely. He reiterates an Outperform rating on Regeneron shares.
05/23/17
JEFF
05/23/17
NO CHANGE
Target $418
JEFF
Hold
Regeneron approval expected, but positive, says Jefferies
Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.
05/05/17
LEER
05/05/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron price target raised to $493 from $448 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $493 from $448 following quarterly results, and given the strength of peer company multiples and greater conviction about long-term profitability. The analyst reiterates an Outperform rating on the shares.
NVDA Nvidia
$157.32

5.7 (3.76%)

06/20/17
06/20/17
DOWNGRADE

Sector Weight
ON Semiconductor downgraded to Sector Weight from Overweight at Pacific Crest
Pacific Crest analyst Michael McConnell downgraded ON Semiconductor (ON) to Sector Weight after Asia supply-chain channel checks left him "incrementally more cautious." Signs of double-ordering by customers raises risk of a correction over the next 12 months, McConnell tells investors in a research note. He recommends investors move to the sidelines with respect to the shares. The analyst this morning also upgraded Nvidia (NVDA) to Sector Weight and Marvell Technology (MRVL) to Overweight.
06/20/17
06/20/17
UPGRADE

Sector Weight
Nvidia upgraded to Sector Weight from Underweight at Pacific Crest
Pacific Crest analyst Michael McConnell upgraded Nvidia to Sector Weight after Asia supply-chain channel checks left him "incrementally more positive." Strong GPU demand from the cryptocurrency mining market has "rapidly depleted excess channel inventory" carried into Q2 and reduces gaming segment growth concerns in FY18, McConnell tells investors in a research note.
06/15/17
RAJA
06/15/17
INITIATION
Target $175
RAJA
Outperform
Nvidia resumed with an Outperform at Raymond James
Raymond James analyst Chris Caso resumed coverage on Nvdia with an Outperform and a $175 price target saying valuation is being driven by long-term Datacenter and Auto potential and shares should continue higher if those segments continue to advance and the core business remains stable.
06/15/17
WELS
06/15/17
NO CHANGE
WELS
Nvidia likely to encounter competition in accelerators, says Wells Fargo
Wells Fargo believes that "several different classes of (datacenter) accelerators" will emerge. The firm says that Nvidia's accelerators "are optimized for some specific types of applications" i.e. graphics or image processing,leaving the door open for processors that are stronger in other areas. Wells keeps an Underperform rating on Nvidia.
LH LabCorp
$144.36

2.465 (1.74%)

02/06/17
BARD
02/06/17
DOWNGRADE
Target $138
BARD
Neutral
LabCorp downgraded to Neutral at Baird
As previously reported, Baird analyst Whit Mayo downgraded LabCorp to Neutral from Outperform as he is less convinced the company can grow earnings double digits in 2017, the current valuation is above historical averages, and he does not see an M&A deal that would meaningfully alter the risk/reward. Mayo has a $138 price target on LabCorp shares.
05/09/17
JEFF
05/09/17
NO CHANGE
Target $66
JEFF
Hold
Parexel sale best way to fix company, says Jefferies
Jefferies analyst David Windley believes a sale of Parexel (PRXL), which the Wall Street Journal reported yesterday is under consideration, is "likely the best way to fix the company for many reasons." Parexel has been suggested as one of LabCorp's (LH) interests, but LabCorp management may not want to take on such a deal, Windley tells investors in a research note. Parexel changes are more easily undertaken in private, he contends. The analyst has a Hold rating on the shares with a $66 price target.
02/06/17
02/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AutoNation (AN) downgraded to Hold from Buy at Evercore ISI with analyst Michael Montani saying calendar year 2017 is shaping up to be an investment year and reduced estimates. The analyst said the AutoNation USA brand extension strategy means fewer franchised acquisitions and more pre-open expense for this year and next. 2. LabCorp (LH) downgraded to Neutral from Outperform at Baird with analyst Whit Mayo saying he is less convinced the company can grow earnings double digits in 2017, the current valuation is above historical averages, and he does not see an M&A deal that would meaningfully alter the risk/reward. 3. Tiffany (TIF) downgraded to Neutral from Buy at Mizuho and to Hold from Buy at HSBC. 4. CVS Health (CVS) downgraded to Neutral from Overweight at Atlantic Equities. 5. NVIDIA (NVDA) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying he "struggles" to articulate a valuation-driven for the stock meaningfully above current trading levels. Nonetheless, the analyst expects another "outstanding result" when the company announces earnings this week. He raised his price target on the shares to $120 from $95. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/17/17
ADAM
02/17/17
NO CHANGE
Target $150
ADAM
Buy
LabCorp price target raised to $150 from $140 at Canaccord
Canaccord analyst Mark Massaro raised his price target on LabCorp to $150 from $140 following better than expected Q4 results. The analysts feels the company guidance is set appropriately and that shares are cheap. Massaro said it remains one of his top five picks, citing the potential for improving multiple expansion and solid free cash flow. Massaro reiterated his Buy rating on LabCorp shares.
DHI D.R. Horton
$34.75

0.9 (2.66%)

04/21/17
RBCM
04/21/17
NO CHANGE
RBCM
D.R. Horton should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that D.R. Horton reported "strong" Q2 results, The analyst raised his price target on the stock to $37 from $35 and keeps an Outperform rating on the shares. He recommends buying the shares on weakness.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
D.R. Horton acquisition of Forestar Group would be positive, says Wells Fargo
After D.R. Horton (DHI) made an unsolicited bid for Forestar Group (FOR), Wells Fargo says that acquiring Forestar would enable D.R. Horton "to grow at a double digit rate while mitigating incremental risk." The analyst says that the deal would give D.R. Horton "a solid competitive advantage" and enable it to grow more quickly while "mitigating potential impairment risk through the cycle." Wells thinks that D.R. Horton will enter into a "bidding war" with Starwood Capital, which had previously agreed to take Forestar private for $14 per share. Wells keeps an Outperform rating on D.R. Horton.
04/21/17
WELS
04/21/17
NO CHANGE
WELS
D.R. Horton weakness overdone, says Wells Fargo
After D.R. Horton provided lower than expected 2H17 revenue guidance and the stock sank, Wells Fargo says the company reported many strong data points. It says that the company's outlook remains positive, and it recommends buying the shares on weakness.
05/16/17
MZHO
05/16/17
INITIATION
Target $32
MZHO
Neutral
D.R. Horton initiated with a Neutral at Mizuho
Mizuho analyst Haendel St. Juste initiated D.R. Horton with a Neutral and a $32 price target.

TODAY'S FREE FLY STORIES

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.60

0.46 (0.16%)

12:36
01/19/18
01/19
12:36
01/19/18
12:36
Periodicals
Trump seeks meeting with Schumer to avert shutdown, NY Times reports »

Maggie Haberman of the…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.60

0.46 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:31
01/19/18
01/19
12:31
01/19/18
12:31
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana resumes, up 43% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.49

0.35 (0.13%)

, IEMG

iShares Core MSCI Emerging Markets

$60.61

0.305 (0.51%)

12:30
01/19/18
01/19
12:30
01/19/18
12:30
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows continued to be…

SPY

SPDR S&P 500 ETF Trust

$279.49

0.35 (0.13%)

IEMG

iShares Core MSCI Emerging Markets

$60.61

0.305 (0.51%)

IEFA

iShares Core MSCI EAFE ETF

$69.52

0.215 (0.31%)

EWJ

iShares MSCI Japan Index Fund

$63.74

0.31 (0.49%)

BNDX

Vanguard Total International Bond ETF

$54.18

-0.02 (-0.04%)

EEM

MSCI Emerging Markets Index

$50.31

0.2775 (0.55%)

IWM

iShares Trust Russell 2000 Index Fund

$157.91

1.37 (0.88%)

GLD

SPDR Gold Trust

$126.65

0.79 (0.63%)

SVXY

ProShares Short VIX Short-Term Futures

$131.85

-0.45 (-0.34%)

IWD

iShares Russell 1000 Value

$128.57

0.09 (0.07%)

JNK

SPDR Barclays High Yield Bond

$36.80

-0.015 (-0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.83

-0.315 (-0.26%)

IEF

iShares 7-10 Year Treasury Bond ETF

$104.06

-0.33 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:30
01/19/18
01/19
12:30
01/19/18
12:30
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$162.44

-6.68 (-3.95%)

, AXP

American Express

$97.11

-2.75 (-2.75%)

12:29
01/19/18
01/19
12:29
01/19/18
12:29
General news
On The Fly: Top stock stories at midday »

Stocks opened with minor…

IBM

IBM

$162.44

-6.68 (-3.95%)

AXP

American Express

$97.11

-2.75 (-2.75%)

GE

General Electric

$16.35

-0.425 (-2.53%)

ACOR

Acorda Therapeutics

$25.00

0.25 (1.01%)

BIIB

Biogen

$344.44

-0.43 (-0.12%)

NKE

Nike

$66.64

2.525 (3.94%)

IPHI

Inphi

$33.39

-2.01 (-5.68%)

MKC

McCormick

$98.72

-4.19 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 07

    Feb

  • 08

    Mar

EA

Electronic Arts

$115.28

2.14 (1.89%)

, ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

12:28
01/19/18
01/19
12:28
01/19/18
12:28
Hot Stocks
EA in focus after NPD says 'Battlefront II' second-best selling game in December »

Shares of Electronic Arts…

EA

Electronic Arts

$115.28

2.14 (1.89%)

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

12:25
01/19/18
01/19
12:25
01/19/18
12:25
General news
Treasury's $25 M 6-day CMB stopped at 1.210% »

Treasury's $25 M…

BHGE

Baker Hughes

$34.63

-0.11 (-0.32%)

12:20
01/19/18
01/19
12:20
01/19/18
12:20
Options
Put buying in Baker Hughes ahead of earnings »

Put buying in Baker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.70

0.55 (3.63%)

12:19
01/19/18
01/19
12:19
01/19/18
12:19
Hot Stocks
Breaking Hot Stocks news story on Momenta 

Momenta trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
01/19/18
01/19
12:17
01/19/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$7.35

0.05 (0.68%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
NuCana to resume trading at 12:30 pm ET »

NuCana is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta jumps 14%, halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$14.27

0.18 (1.28%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Options
MiMedx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Periodicals
Breaking Periodicals news story on Momenta »

Momenta weighing options,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$26.50

-0.31 (-1.16%)

12:05
01/19/18
01/19
12:05
01/19/18
12:05
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMNB

American National Bankshares

$39.10

-0.8 (-2.01%)

12:03
01/19/18
01/19
12:03
01/19/18
12:03
Hot Stocks
American National Bankshares announces 300,000 share repurchase program »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIB

Porter Bancorp

$13.76

0.06 (0.44%)

12:02
01/19/18
01/19
12:02
01/19/18
12:02
Hot Stocks
PBI Bank changes name to Limestone Bank »

In the first weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:01
01/19/18
01/19
12:01
01/19/18
12:01
Hot Stocks
NuCana reports 'promising' clinical data on Acelarin »

NuCana announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$46.51

-0.27 (-0.58%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Options
Mylan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

BTC

Bitcoin

, BAC

Bank of America

$31.55

0.07 (0.22%)

11:52
01/19/18
01/19
11:52
01/19/18
11:52
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

BAC

Bank of America

$31.55

0.07 (0.22%)

MS

Morgan Stanley

$56.67

0.83 (1.49%)

GS

Goldman Sachs

$252.15

1.18 (0.47%)

V

Visa

$122.10

-1.015 (-0.82%)

AMD

AMD

$12.47

0.29 (2.38%)

NVDA

Nvidia

$224.44

-0.28 (-0.12%)

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

DPW

DPW Holdings

$2.30

-0.05 (-2.13%)

LBCC

Long Blockchain Corp.

$4.51

0.3 (7.13%)

KODK

Kodak

$10.05

-0.1 (-0.99%)

SSC

Seven Stars Cloud Group

$4.53

-0.1 (-2.16%)

RIOT

Riot Blockchain

$19.80

2.04 (11.49%)

LFIN

Longfin

$44.69

6.09 (15.78%)

TEUM

Pareteum

$2.37

0.01 (0.42%)

SRAX

Social Reality

$4.96

0.17 (3.55%)

GBTC

Bitcoin Investment Trust

$1,857.00

221 (13.51%)

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 15

    Feb

AOS

A.O. Smith

$66.32

0.41 (0.62%)

11:51
01/19/18
01/19
11:51
01/19/18
11:51
Hot Stocks
A.O. Smith announces 29% boost in dividend »

Directors of A. O. Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.